Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Avextra","sponsor":"German Pain Association","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Avextra

    Menu

    Avextra

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Avextra

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN

              Details:

              The company is aiming to concentrate on the clinical advancement of THC:CBD (Tetrahydrocannabinol), a partial agonist of the CB1 receptor with Cannabidiol. Both controlled substances will undergo evaluation for the treatment of chemotherapy-induced neuropathic pain.

              Lead Product(s): Tetrahydrocannabinol,Cannabidiol

              Therapeutic Area: Neurology Product Name: THC:CBD

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: German Pain Association

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 23, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY